title: Pretreatment with feline interferon omega and the course of subsequent infection with feline herpesvirus in cats.
abstract: OBJECTIVE
  Recombinant feline interferon omega (rFeIFN-omega), a type I IFN, may have the potential to limit virus replication and associated clinical signs when administered early on in the course of feline herpesvirus type 1 (FHV-1) infection and reactivation, respectively. The effect of rFeIFN-omega pretreatment on the course of subsequent FHV-1 infection in cats was investigated.
  
  
  METHODS
  Nine SPF cats were divided into an IFN group (n = 5) and a control-group (n = 4).
  
  
  METHODS
  The IFN group was pretreated for 2 days with 10 000 units rFeIFN-omega twice a day topically into both eyes and 20 000 units rFeIFN-omega once a day orally, whereas the control group was mock-treated. Subsequently all cats were infected with FHV-1. Samples for FHV-1 DNA detection and quantitation, virus isolation, and titration of FHV-1 antibodies were collected. Clinical and ocular signs were recorded and scored.
  
  
  RESULTS
  Courses of median individual clinical and ocular scores and virus load did not differ significantly between both groups using anova for repeated measurements. Analysis (anova) of each individual ocular parameter revealed significantly high scores for epithelial keratitis (P = 0.016) in the IFN group compared to the control group. Periods of virus shedding did not differ significantly between both groups using the Wilcoxon rank sum test.
  
  
  CONCLUSIONS
  Results indicated a lack of beneficial effects of rFeIFN-omega pretreatment in the course of primary FHV-1 infection in cats.
authors.affiliation: Department of Small Animals, Ophthalmology Unit, Vetsuisse Faculty, University of Zürich, Winterhurerstrasse 260, 8057 Zürich, Switzerland.
authors.forename: Clemens
authors.initials: C
authors.lastname: Haid
authors.forename: Simone
authors.initials: S
authors.lastname: Kaps
authors.forename: Enikö
authors.initials: E
authors.lastname: Gönczi
authors.forename: Michael
authors.initials: M
authors.lastname: Hässig
authors.forename: Alfred
authors.initials: A
authors.lastname: Metzler
authors.forename: Bernhard M
authors.initials: BM
authors.lastname: Spiess
authors.forename: Marianne
authors.initials: M
authors.lastname: Richter
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000704:Analysis of Variance; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002371:Cat Diseases / Q000276:immunology / Q000517:prevention & control*; D002415:Cats; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006564:Herpesviridae / Q000472:pathogenicity; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D007370:Interferon Type I / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D011897:Random Allocation; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D004279:DNA, Viral; D007370:Interferon Type I; C063743:interferon omega 1